chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This is a spontaneous report from a contactable consumer reporting for herself. A 70-years-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection), via an unspecified route of administration, administered in Arm Left on Jan2021 06:45 PM (Batch/Lot Number: EL9261) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. The patient previously took clarithromycin (MACROBID), T-DAP vaccine and experienced drug hypersensitivity. The patient did not receive any other vaccines within four weeks prior to the vaccination and other medications in two weeks as Statin. Prior or post to the vaccination, the patient was not diagnosed with COVID-19. On 29Jan2021, patient experienced, extreme soreness on scalp. Reported as "two days after vaccine on the left and six days after vaccine on the right. Each lasted about 24 hours" Patient did not receive any treatment for the events. The clinical outcome of the event was recovered on an unspecified date.  Follow-up attempts are completed. No further information is expected.
Headache - intermittent lasting from 2/2/21 - 2/5/21; worst 2nd day, 2/3/21 Body aches - lasting from 2/2/21 at 11:00 p.m. - 2/5/21 (afternoon) Symptoms occurred at home.
Moderna COVID?19 Vaccine EUA Swelling and rash at injection site a week after first dose. Looks like what?s known as covid arm
6/1/21 PMH significant for CAD s/p PCI and 3 vessel CABG 2010 (LIMA-LAD, SVG-RCA, SVG-OM), HFrEF (~20% 8/2020), atrial fibrillation on Coumadin, MR, T2DM, HTN, HLD, PVD . Presented w/chief complaint of dyspnea on exertion.
3 days after vaccine, I had intense shoulder pain that radiated to right arm and felt like I hit my funny bone. It went into my palm and 2 outer fingers. The next day I went to chiropractor thinking I had a pinched nerve in my neck or back and I went there and I didn't get any relief, so I went to another chiropractor and he used a heat probe and stretched my neck and I used alternating hot and cold packs on that shoulder and had no relief. I went to my PCP and by that time my little finger and ring finger of right arm were continuously numb and they're still numb now today and never improved since my shot. My PCP didn't know what it was and he prescribed Gabapentin that I began taking and recommended I went to see my neurologist and he did a x-ray on April 11, a CT scan on April 14, and an EMG on April 26 and diagnosed me with Parsonage Turner Syndrome and he increased my steroid to 64 mg for 7 days alternating 32 mg for 7 days and then after that I went back to my 64 mg once a week. I never returned to Chiropractor and my pain from that Covid shot went away with steroid treatment but the fingers never got better. At the end of September and I don't know if this had anything to do with the vaccine but I developed shingles on my right side and then I was prescribed Gabapentin an Tramadol which I'm still taking a month later. I'm still having intense shingle pain in right side. Dr. is familiar with my auto immune disease and I saw Dr. on Tuesday and asked him about the Covid Booster and shingles shot and he recommended I delay getting the booster for a number of months and the shingles shot I can't take while I have shingles so that will be sometime down the line too.
Over phone mother describes swelling in left armpit and pt experiencing nausea on morning of 1/15/2014 RPh - normal adverse reaction for age group - reported back info to mother and told her if symptoms did not improve in 24-48 contact Dr left message for follow up care 1/16/14.
On 1-23-2008 employee was given first dose of the MMR vaccine at 8:20am she stayed in this office until 8:50am for routine observation. At 9:00 am she started feeling numbness, swelling and tingling in her lips and tongue after returning to her job. She then c/o of sharp chest pain in right side of chest and that it also felt hot. B/P was elevated. She was taken to emergency room for further evaluation at 12:00 noon. (she did not want to go to er prior) patient was kept for several hours in the er and monitored for any cardiac problems all test for negative and dx chest pain "uncertain cause". She was seen here on 1-24-08 for follow up a rash had developed over chest, back, neck. She was taking Benadryl otc. Dr. saw her on 1/24/08 gave her prescription for Sterapred #6. I spoke with employee on 1-25-08 and 1-28-08 she was doing fine rash had gone no swelling or itching or chest pain.  She has declined to take the second dose of MMR.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On an unknown date the patient was vaccinated with improperly stored PEDVAXHIB (lot # L004738, expiration date: 10-NOV-2017, dose and route were not reported). Concomitant drug was not reported. The vaccine had exposed to 32.4 F temperature for 2 hours and 15 minutes without previous temperature excursion. No adverse event was reported. This is one of the several reports from the same reporter. Additional information has been requested.
she is struggling to get up; she feels like she has the flu.; body aches, her whole body hurts, pain; This spontaneous case was reported by a patient and describes the occurrence of DYSSTASIA (she is struggling to get up), INFLUENZA (she feels like she has the flu.) and MYALGIA (body aches, her whole body hurts, pain) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 053C21A) for COVID-19 vaccination.     Concomitant products included IBUPROFEN (ADVIL [IBUPROFEN]), VITAMINS NOS and VITAMIN C [ASCORBIC ACID] for an unknown indication.   On 17-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jun-2021, the patient experienced DYSSTASIA (she is struggling to get up), INFLUENZA (she feels like she has the flu.) and MYALGIA (body aches, her whole body hurts, pain). At the time of the report, DYSSTASIA (she is struggling to get up), INFLUENZA (she feels like she has the flu.) and MYALGIA (body aches, her whole body hurts, pain) outcome was unknown.            Concomitant medication  unspecified  OTC Heartburn medication and unspecified Anti Anxiety medication.  Treatment information were not Advil provided.
SHORTNESS OF BREATH; TINGLING/NUMBNESS ALL OVER THE ARM; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 203A21A, and expiry: UNKNOWN) dose was not reported, administered on 12-MAY-2021 for prophylactic vaccination. No concomitant medications were reported.  On an unspecified date, the subject experienced shortness of breath, and tingling/numbness all over the arm. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from shortness of breath, and tingling/numbness all over the arm. This report was non-serious.
Father reports onset 1 day ago of left thigh swelling, erythema, pain, and itching at the injection site.  States it is getting worse.
Tested positive for COVID after receiving the vaccination.  Symptoms began on 9/28/2021.  She had SOB burning lungs, nausea, loss of taste and smell, migraines, stuffy nose and sore throat.  She was also hospitalized for 4 days from 10/1/2021 thru 10/5/2021
Initial report received from a physician on 19 April 2007. A 19 year old, female patient developed swelling of both eyes after she received her second dose of JE-VAX (lot number EJN228A) subcutaneously in the right arm on 09 April 2007. She also had a sore throat, congestion and lymph node enlargement-neck. She received her first dose of JE-VAX (lot number EJN228A) subcutaneously in the left arm on 02 April 2007. She was treated with Benadryl on 18 April 2007. At the time of the report, she had not recovered. Follow up information received on 02 July 2007 from a physician in USA; The patient had recovered. No sensitization tests done as she declined further service since 20 April 2007. On 23 April 2007 the patient's mother reported that the patient diagnosed with "mono" and "UTI". On 08 May 2007 the patient did not report any prolonged symptoms. Follow-up information received on 23 July 2007 from a health care professional. The reported events were confirmed as mononucleosis and urinary tract infection. Per the reporter, any laboratory results done between 20 April and 23 April were done by the patient's primary care physician "not my clinic."
Pain on left arm (place where I took the vaccine), shoulder, neck and upper back. I took the vaccine a month ago, and still hurting a lot. also, I am feeling weak and tired.
Persistent left shoulder pain and inability to move shoulder that started about 60 hours after vaccine and is still present over 10 days later
Site red, swollen, hot to touch. Rx KEFLEX resolved after 2 days.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. No information was provided regarding concomitant medications, concurrent conditions or medical history. On or about 11-JAN-2012, the patient was inoculated with ZOSTAVAX at a medical center (considered a hospital) as recommended for routine adult health maintenance for the prevention of shingles (dose, route, and lot # not provided).  The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain of herpes zoster, also known as shingles and other complications. Later in 2012, the patient was treated at the same medical center (not specified whether admitted; therefore, considered an Emergency Room visit until follow-up is received) for a blistering vesicular outbreak, that was diagnosed as severe herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
Convulsion- eyes rolled back, involuntary contraction of muscles, unresponsive, lasted 10 seconds other symptoms: chills, nausea, sweating
administering intranasal; This case was reported by a nurse via call center representative and described the occurrence of intramuscular formulation administered by other route in a 14-year-old male patient who received Flu Seasonal QIV (FluLaval Quadrivalent 2022-2023 season) (batch number 3393T, expiry date 30th June 2023) for prophylaxis.   Co-suspect products included flu seasonal qivpre-filled syringe device (Flulaval Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 25th October 2022, the patient received FluLaval Quadrivalent 2022-2023 season (intranasal) and Flulaval Tetra Pre-Filled Syringe Device. On 25th October 2022, unknown after receiving FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device, the patient experienced intramuscular formulation administered by other route. On an unknown date, the outcome of the intramuscular formulation administered by other route was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 26-Oct-2022 Reporter's comment: The health department had a flu clinic one day before the reporting date. The reporter reported that they were administering Flulaval and an intranasal flu vaccine and a nurse volunteer gave Flulaval intranasally to 3 patients. The vaccine administration facility was the same as primary reporter. The facility address was also reported above in health care professional's details. The reporter consented to follow-up by phone. This was for 1 of 3 linked cases reported by same reporter. Additional supportive information: The patient received Flulaval vaccine intranasally, which led to intramuscular formulation administered by other route.; Sender's Comments:  US-GSK-US2022154656:Same reporter US-GSK-US2022154657:Same reporter
Reported that child was in clinic with mother and that mother brought child to admitting desk stating "he was not breathing right."  Reported that child was brought back to exam area and noted to have tonic-clonic gestures.  No history of seizures.  Reported that child was afebrile (temp 99 axillary).  IV access obtained; O2 sat 99% on O2.  EMS at bedside.  Child to ER; child noted to be postictal and responsive upon transfer.  Pediatrician assessed child after incident; not present at initiation of episode.
Pt. states that after receiving the 2nd dose of Phizer 10/01/2021, started experiencing symptoms 10/06/2021 of heart palpations, dizziness, faint, shortness of breath, difficulty lifting, and leg weakness. Urgent Care visit estimated 10/15/2021, recommendation prescribing Inflammation (Ibuprofen 800mg). 11/12/2021 Faintness during driving, resulting in family member transporting. Primary Appt. scheduled 12/03/2021.
Pt was given vaccine and asked to wait 15 min. After patient was seated in waiting area around 5 minutes after receiving vaccine she began to vomit and felt lightheaded. Her father did confirm during this that she has had a history of anxiety after vaccines and this has occurred previously with other vaccines. Patient was given a coke to drink and an icepack while being monitored by our staff. We will follow-up with family tomorrow to make sure patient is doing okay.
ELECTRICAL IMPULSES ON BACK AND LEGS; TAPPING ON HEAD; TINGLING SENSATION ON FACE NEAR MOUTH LIKE ELECTRICAL IMPULSES; This spontaneous report received from a patient concerned a 64 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included non alcoholic, and non smoker, and other pre-existing medical conditions included the patient had no medical history present the patient had no known allergies and no drug abuse or illicit drug usage. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1802068, and expiry: UNKNOWN) dose was not reported, administered on 07-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 07-MAR-2021, the subject experienced tingling sensation on face near mouth like electrical impulses. On 10-MAR-2021, the subject experienced tapping on head. On 21-MAR-2021, the subject experienced electrical impulses on back and legs. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from tingling sensation on face near mouth like electrical impulses on 07-MAR-2021, and tapping on head, and had not recovered from electrical impulses on back and legs. This report was non-serious.
This spontaneous report was received from a physician via company representative, and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not reported. On 10-MAR-2014, the patient was vaccinated with a dose of improperly stored PNEUMOVAX 23 "10 Single dose 0.5mLVIs 10SDV" and lot number J009689 with expiration date of 29-JAN-2015 (route of administration was unknown), which was stored at 34 Fahrenheit (F) Degrees (1.111111111 Celsius)for a total of 144 hours. The vaccine status was reported as "in excursion". The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator(R)". No adverse effect were reported nor product quality complaint was involved. This is one of several cases received from the same reporter. Additional information has been requested.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66-year-old female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), in 2023 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Glaucoma" (unspecified if ongoing); "pericardial effusion" (unspecified if ongoing). Concomitant medication(s) included: COSOPT PF. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 3 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 immunisation. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "recovered" (Oct2023) and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Oct2023) Negative. Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid. Clinical course: Rebound symptoms one week after testing negative.  The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300335758 Same patient, different drug, different event;
Pain, inflammation, bruising, swelling, dry throat, swollen lymph glands, general malaise
Swelling and redness left thigh, temperature, Benadryl and Tylenol.
FEVER; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 18-MAR-2021 for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On JUN-2021, the subject experienced fever. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 103.5 (Unit not reported). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of fever was not reported. This report was non-serious.
HE CAME IN THE MORNING FOR HIS APPOINTMENT, IN WHICH WE GAVE HIM A FLU SHOT.  MOM CALLED IN THE AFTERNOON  TO SAY THAT HE STARTED HAVING SWELLING AROUND THE EYES.  SHE ALSO NOTED THAT IT WAS HIS FIRST FLUSHOT, BUT ALSO HAD SOME AVOCADO THAT DAY.  MOM HAS A KNOWN ALLERGY TO AVOCADO, AND WASN'T SURE IF THIS WAS ALSO THE CASE FOR HIM.
Per patient, by the time she went to bed on night of immunization, she had fever and chills along with an upset stomach (that she had attributed to wine earlier in the evening). Her left arm was hot and swollen, and by third day, there was a pattern down to almost her elbow that was red and itchy. She has since recovered. Patient does not have primary doctor, and has not seen a doctor, but notified the pharmacy today about the adverse event when stopping in to check on availability of a different immunization.
I had my second COVID vaccine on 4/2/21 and ever since then I have been bleeding. I take an oral contraceptive. I reached out to my OB/GYN who suggested I stop taking them for about five days then restart the oral contraceptive a a double dose for five days. I was told to contact the office again if this did not stop the bleeding as I would need an ultrasound . It worked for about a week and now I?m bleeding again and will be contacting my doctors office.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 05Feb2021 as dose 1, single (Lot number: EM9810), in left arm, on 26Feb2021 as dose 2, single (Lot number: EN6198), in left arm and on 17Nov2021 as dose 3 (booster), single (Lot number: FH8028) at the age of 66 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (12Sep2022) Negative; (15Sep2022) Negative; (15Sep2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: Antiviral details included PAXLOVID for COVID 19 Treatment (Treatment start date: 05Sep2022; Treatment stop date: 10Sep2022. On 05Sep2022 prescribed PAXLOVID, on 12Sep2022, tested negative; on 15Sep2022 tested negative; on 15Sep2022 tested positive. On 15Sep2022 tested positive told by doctor the patient had COVID rebound.  No follow-up attempts are possible. No further information is expected.
12JAN94 feverish, itchy for 3 days then broke out in hives; seen by MD & given cortisone for hives;
Deviation from the recommended dosing interval; Patient contracted COVID-19 after the first vaccination; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Deviation from the recommended dosing interval) and SARS-COV-2 TEST POSITIVE (Patient contracted COVID-19 after the first vaccination) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Deviation from the recommended dosing interval) and SARS-COV-2 TEST POSITIVE (Patient contracted COVID-19 after the first vaccination). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Deviation from the recommended dosing interval) had resolved and SARS-COV-2 TEST POSITIVE (Patient contracted COVID-19 after the first vaccination) outcome was unknown. Unknown      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
ADMINISTERED ANOTHER DOSE OF VACCINE IN JUNE AS THEY DIDN'T KNOW HE HAD HIS INITIAL DOSE IN MARCH; This spontaneous report received from a consumer concerned a male of unspecified age. The patient's height, and weight were not reported. The patient's concurrent conditions included: alzheimer's The patient's pre-existing medical conditions included: After the first dose of vaccine the patient was admitted to a residential facility due to his alzheimer that he had from before. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on MAR-2021, and dose was not reported, administered on JUN-2021 for prophylactic vaccination, and prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the patient experienced administered another dose of vaccine in june as they didn't know he had his initial dose in march. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of administered another dose of vaccine in june as they didn't know he had his initial dose in march was not reported. This report was non-serious.
3JUN94 began fever, had chills & sweats 3JUn & 4JUN then started cramps & pain in rt upper quad w/more chills & fever; also nausea; no vomiting;